TSO3 Inc

TSO3 — Shareholder Meeting (May 2014)

56 slides from TSO3's shareholder meeting presentation, May 7, 2014

  1. Slide 1: Annual General Meeting of the Shareholders

    May 7, 2014 Annual General Meeting of the Shareholders

  2. Slide 2: Germain Carrière, Chairman of the Board

    2 Germain Carrière Chairman of the Board

  3. Slide 3: Agenda of the Meeting

    Agenda of the Meeting 3  Order of the day  Appointment of secretary and scrutineer  Verification of the validity of the Meeting  Conformity of deadline of Notice  Quorum  General Meeting  Financial Results for the period ended December 31, 2013, by Benoît Deschamps, CFO  Appointment of Direc

  4. Slide 4: Annual General Meeting of the Shareholders

    May 7, 2014 Annual General Meeting of the Shareholders

  5. Slide 5: Benoît Deschamps, Financial Results

    5 Benoît Deschamps Chief Financial Officer Financial Results - Period ended December 31, 2013

  6. Slide 6: Financial Highlights – Fiscal year 2013

    Financial Highlights – Fiscal year 2013 6 Year ‐ 2013 Year ‐ 2012 In thousands dollars $ $ As reported, accounting for One-Line Items Total Revenues 254 2 854 Total Expenses (9 525) (8 649) Total Loss (9 271) (5 795) Loss Per Share (0,13) (0,09) Excluding One-Line Items Total Revenues 254 1 268 Tota

  7. Slide 7: Highlights - Q1 2014

    Highlights - Q1 2014 7 In thousands dollars $ $ As reported Revenues 82 76 Net Loss 1 561 2 100 Net Loss Per Share 0,02 0,03 Excluding Additionnal R&D Tax Credits Revenues 82 76 Net Loss 1 798 2 100 Net Loss Per Share 0,02 0,03

  8. Slide 8: Revenue Retrospective

    Revenue Retrospective 8 In thousands dollars In thousands dollars 2,500 4,000 3,500 2,000 3,000 1,500 2,500 2,000 1,000 1,500 1,000 500 500 - - Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 2010 2011 2012 2013

  9. Slide 9: Expenses Retrospective

    Expenses Retrospective 9 In thousands dollars In thousands dollars 4,500 12,000 4,000 10,000 3,500 3,000 8,000 2,500 2,000 6,000 1,500 4,000 1,000 500 2,000 - - Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 (50

  10. Slide 10: Financial Results

    Financial Results 10 In In Q1-2010 Q2-2010 Q3-2010 Q4-2010 Q1-2011 Q2-2011 Q3-2011 Q4-2011 Q1-2012 Q2-2012 Q3-2012 Q4-2012 Q1-2013 Q2-2013 Q3-2013 Q4-2013 Q1-2014 thousands thousands dollars dollars 2010 2011 2012 2013 0 0 -500 -1,000 -2,000 -1,000 -3,000 -1,500 -4,000 -2,000 -5,000 -2,500 -6,000 -7

  11. Slide 11: Cash Burn Rate

    Cash Burn Rate 11 1,400 In thousands dollars In thousands dollars 2010 2011 2012 2013 1,200 - 1,000 36-month (2,000) average 800 burn rate of $642,408 600 2013 (4,000) average burn rate of 400 $615,644 (6,000) 200 0 (8,000) (10,000) Burn Rate - Actual Burn Rate - Actual Burn Rate - Adjusted for unus

  12. Slide 12: Financial Condition - Runway

    Financial Condition - Runway 12  Liquidities at  December 31, 2013: $9,609,000  March 31, 2014: $8,980,000 $ 12,000,000 10,000,000 8,000,000 6,000,000 4,000,000 2,000,000 0 36-month burn rate of $642,000 Q1-2014 adjusted burn rate of $550,000

  13. Slide 13: Agenda of the Meeting

    Agenda of the Meeting 13  Order of the day  Appointment of secretary and scrutineer  Verification of the validity of the Meeting  Conformity of deadline of Notice  Quorum  General Meeting  Financial Results for the period ended December 31, 2013, by Benoît Deschamps, CFO  Appointment of Dire

  14. Slide 14: Annual General Meeting of the Shareholders

    May 7, 2014 Annual General Meeting of the Shareholders

  15. Slide 15: R.M. (Ric) Rumble, President and CEO

    15 R.M. (Ric) Rumble President and Chief Executive Officer

  16. Slide 16: Forward-looking Information

    Forward-looking Information 16 The speeches made during this meeting may include forward-looking information with respect to the Company, including its business operations, strategy, financial performance and condition. Although management of the Corporation believes that the conclusions, estimates

  17. Slide 17: Our Vision

    Our Vision 17 Creating the Improved Standard in Healthcare Sterile Reprocessing

  18. Slide 18: Key Historic Events

    Key Historic Events 18 1998-2008 • Initial sterilization platform (limitations in offering as per cycle times and compatibility)  Regulatory clearance in Canada and the United States  Sold directly by TSO3 with limited success (38 units/5 years) 2009-2010 • Renewed direction • Second generation st

  19. Slide 19: Where we have come from / Where we are

    Where we have come from / Where we are 19 TSO3 Files for Commercial Clearance in the United States - June 30, 2011 - TSO3 resubmits documents to De Novo proceed with US regulatory clearance 510(k) - April 20, 2012 - TSO3 Files New and Simplified TSO3 and 3M agree to global Submission to the US chann

  20. Slide 20: FDA ...Why so long?

    FDA ...Why so long? 20 510(k) process: Compare new device to an existing legally cleared device Challenge: Introduce “innovation” while demonstrating “similar” to existing device  2009 – 2010  Changes in the Guidance document  Not Substantial Equivalent (NSE) based on predicate  2011- 2013  Mec

  21. Slide 21: USA Regulatory Strategy

    USA Regulatory Strategy 21  New 510(k) Submission  Incorporating previously substantiated data and  Data collected on our Device and Predicates as guided by the US Regulatory Authorities in the January 2014 response

  22. Slide 22: FDA ...Why so long?

    FDA ...Why so long? 22  STERIZONE® VP4 Sterilizer  USA only  Similar but DIFFERENT from REST OF THE WORLD Sterilizer  One Cycle  Broadest claim, largest load in industry  Relies solely on Hydrogen Peroxide as active Sterilant  Elevated H2O2 MEC  Utilizes Ozone to remove residual H202  Remov

  23. Slide 23: Comparison of STERIZONE 125L+ and VP4 Sterilizers

    Comparison of 23 STERIZONE® 125L+ and VP4 Sterilizers STERIZONE® 125L+ Sterilizer (1) STERIZONE® VP4 Sterilizer (2) Cycle 1 Cycle 2 Cycle 3 Single channel flexible endoscopes  Inside diameter of 1.0 mm or larger and length of 850 mm or shorter Cycle Time 46 56 100 (minutes) Application Single-chann

  24. Slide 24: What differentiates TSO3

    What differentiates TSO3 24 Predicate Devices Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4 lb 21.4 lb 10.7 lb 13.2 lb

  25. Slide 25: What differentiates TSO3

    What differentiates TSO3 25 Predicate Devices Broad Sterilization Claims Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4

  26. Slide 26: What differentiates TSO3

    What differentiates TSO3 26 Broad Sterilization Claims Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle cycle cycle Lumen cycle Maximum 75 lb load weight (+ 25 lb 21.4 lb 21.4 lb 10.7 lb

  27. Slide 27: What differentiates TSO3

    What differentiates TSO3 27 Predicate Devices Predicate Devices offer multiple cycles which are both instrument and load size restricted Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle

  28. Slide 28: What differentiates TSO3

    What differentiates TSO3 28 Predicate Devices Predicate Devices offer multiple cycles which are both instrument and load size restricted Parameters STERIZONE® 100NX 100NX 100NX 100NX V-PRO maX V-PRO maX V-PRO maX VP4 cycle Standard Flex Scope EXPRESS DUO cycle Flex Scope Lumen Non cycle cycle cycle

  29. Slide 29: Both Sterilizers are covered by existing and planned patent coverage

    Both the STERIZONE® 125L+ and the VP4 Sterilizers are covered by existing and planned patent coverage 29 Patent US Publication Filing date Title Implemented Implemented Scope of the protection sought Application Number in 125L+ in VP4 in the outside US? US? Original 2011/0076192 29/09/2010 Steriliza

  30. Slide 30: What makes us better?

    What makes us better? 30 While others offer either/or the following benefits:  Efficacy and compatibility  Loading capacity  Speed  We combine them all, allowing for:  Increased throughput  Lowest cost Our solution can replace multiple sterilization technologies

  31. Slide 31: In Summary

    In Summary 31 The STERIZONE® 125L+ and the STERIZONE® VP4 Sterilizers offer protected, rapid cycle time, efficacious, device compatible sterilization, with the highest loading capacity, providing the lowest delivered cost per instrument sterilized

  32. Slide 32: The Opportunity

    32 The Opportunity Increasing demand for low temperature sterile reprocessing

  33. Slide 33: Growing Population

    Growing Population 33 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170‐177.

  34. Slide 34: Aging Population

    Aging Population 34 50% increase 2 billion 605 million 2000 2050 60 yrs+ is the fastest growing segment Individuals 65 yrs+ consume majority of OR time 34 World Health Organization (WHO)

  35. Slide 35: Increase in Surgeries… Some data

    Increase in Surgeries… Some data 35  48 million surgical procedures were performed in the U.S. alone in 2009.  Global cardio-thoracic MIS procedures were around 10 million in 2011, estimated to reach 14 million by 2016.  There were 9 million gastrointestinal procedures in 2011, estimated to reach

  36. Slide 36: Advancement in Surgical Techniques

    Advancement in Surgical Techniques… (Minimally Invasive Surgeries - MIS) 36 Neurosurgery Orthopaedics Pulmonary Medicine Cardiology MIS Gynaecology Gastroenterology Urology …demands development of low temperature sterilization technologies

  37. Slide 37: Rise in Hospital-Acquired Infections (HAI)

    Rise in Hospital-Acquired Infections (HAI) 37 At any given time in every 1 20 infections is related to hospital care in the U.S. alone. Cost of HAI to be absorbed by health care institutions US Department of Health & Human Services

  38. Slide 38: Even more evidence…

    Even more evidence… 38  Three out of 20 gastrointestinal scopes improperly cleaned, contaminated with “Bio Dirt” June 9, 2013 Source: Bommarito M, Thornhill G, Morse D. A Multi-site Field Study Evaluating the Effectiveness of Manual Cleaning of Flexible Endoscopes with an ATP Detection System. Amer

  39. Slide 39: Initial Target: Hospital Sterile Reprocessing

    Initial Target: Hospital Sterile Reprocessing 39 #2 OR OR OR OR OR #1 CS Operating Room Department (OR) OR OR OR OR Central Sterilization (CS) OR Reprocessing and Sterile Storage #3 GI Gastroenterology Department (GI) 39

  40. Slide 40: Market Opportunity

    Market Opportunity 40  CS Worldwide Installed Base  Capital Equipment  $4.5 billion (installed base)  $450 million annually  Consumables US  $250 million annually Canada  OR  Capital Equipment Europe  $600 million in North America only (7,500 units) ROW Defined Large Growing Frost & Sulliva

  41. Slide 41: Accelerated Growth

    Accelerated Growth 41  Transparency Market Research 2013  Sterilization and disinfection devices from $5.13bn to $9.15bn 2013-2019 (CAGR @ 8.5%)  Low Temperature Sterilization fastest growth segment  Projected at 10.9% during the forecasted period

  42. Slide 42: Key Strategic Initiatives

    42 Key Strategic Initiatives

  43. Slide 43: Winning… “Defined”

    Winning… “Defined” 43  FDA clearance…  Channel partner…  Increased portfolio…

  44. Slide 44: Winning… “Defined”

    Winning… “Defined” 44  FDA clearance...  Channel partner...  Increased portfolio...  Products  STERIZONE® 80L Sterilizer  Enhanced cycles  Pass through systems

  45. Slide 45: Partnership Discussions

    Eee Partnership Discussions

  46. Slide 46: User Experience

    User Experience 46  Significantly decreasing (when not eliminating) the use of other methods such as liquid chemicals and toxic ethylene oxide  Using two as it is the preferred method (i.e. back-up system is one of the same) - some already planning to purchase additional units  Improving standard

  47. Slide 47: Channel Partner – History and Approach

    Channel Partner – History and Approach 47  2009-2012  Signed agreement with 3M in December 2009 for the exclusive supply, distribution, license and service of the new STERIZONE® 125L+ Sterilizer.  On June 15, 2012 TSO3 exercised right to terminate the agreement, as provided by the agreement; Sett

  48. Slide 48: Channel Strategy

    Channel Strategy 48  What makes a good partner?  Global in scope  Hungry: They commit their time and resources  Capable: Direct Sales and Service  Bundle: The ability to create “sterilization rooms”  We fill a “GAP” in their portfolio:  Bolt-on product acquisition  Speed to market opportunit

  49. Slide 49: Increase the Portfolio

    49 Increase the Portfolio

  50. Slide 50: Increase the Portfolio

    Increase the Portfolio 50 STERIZONE® 80L Sterilizer • OR sub-sterile • Emerging markets Enhanced cycles • Faster • Gentler Pass through systems • Dirty to Clean

  51. Slide 51: Financial Condition - Runway

    Financial Condition - Runway 51 2009-12-16 2011-06-30 Agreement with 3M 2.5 Re-Submission 2009-12-29 with FDA FDA Filiing and CE Mark 2012-08-02 2 Terminaison of 3M Agreement Announced 1.5 2009-09-02 LOI with 3M 2010-06-08 1 NSE Letter 2013-01-28 0.5 Clean-up 510(k) file submitted 0  December 31, 2

  52. Slide 52: Conserving Resources

    Conserving Resources 52  Collective dismissal – Conserve resources  It was our choice to conserve resources vs. raise capital  Impact  Minimized dilution  Focused efforts on FDA clearance  Monthly Burn Rate  Historical $640,000  Runway available + 1 year  Activities negatively impacted  Ne

  53. Slide 53: Transition

    Transition 53 New directions  2014 is the transitional year for the Company  Focus on FDA clearance  Create the channel partner strategy to be employed post clearance Only then:  Deliver the planned path forward for Shareholder support and milestone measurement

  54. Slide 54: Questions

    Questions 54  When should we expect the FDA Clearance? Answer: We cannot predict the timing of the clearance, rather we can say that the Agency has a total of 90 days to review the file and if they have questions TSO3 will have a total of 180 days to respond.  If TSO3 does not obtain the FDA, do y

  55. Slide 55: Questions

    Questions 55  Does the Company’s Intellectual Property cover the new STERIZONE® VP4 Sterilizer? Answer: Yes please refer to slide 29 which describes the protection of each sterilizer.  By removing the 1.1mm X 3.5m multi-channel device claim in the STERIZONE® VP4 Sterilizer do we lose part of our v

  56. Slide 56: Annual General Meeting of the Shareholders

    May 7, 2014 Annual General Meeting of the Shareholders

TSO3 — Shareholder Meeting (May 2014) on 6ix